SCHEMBL2947880

SCHEMBL2947880

O=C(O)c1ccc(-c2cccc3[nH]ccc23)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.57
HPGDS O60760 2/20 0.55
AURKA O14965 2/20 0.55
TPX2 Q9ULW0 2/20 0.55
ASH1L Q9NR48 1/20 0.52
FTO Q9C0B1 1/20 0.49
PIK3CB P42338 2/20 0.47
PIK3CG P48736 1/20 0.46
MAP2K4 P45985 1/20 0.45
TTR P02766 1/20 0.45
CAMKK2 Q96RR4 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
ENPP2 Q13822 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ABL1 P00519 1/20 0.43
CSNK2B P67870 1/20 0.43
CSNK2A1 P68400 1/20 0.43
PIP4K2A P48426 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22494027 0.86 PIK3CD (0.55) PIK3CDHPGDSAURKATPX2ASH1L
SCHEMBL6319628 0.86 ASH1L (0.67) PIK3CDHPGDSAURKATPX2ASH1L
SCHEMBL2948502 0.82 PIK3CD (0.51) PIK3CDHPGDSASH1LPIK3CBPIK3CG
SCHEMBL27725234 0.81 PIK3CD (0.66) PIK3CDHPGDSASH1LFTOPIK3CB
SCHEMBL5830596 0.81 HPGDS (0.60) PIK3CDHPGDSAURKATPX2ASH1L
SCHEMBL29712113 0.81 PIK3CD (0.70) PIK3CDHPGDSASH1LFTOPIK3CB
SCHEMBL2193011 0.81 PIK3CD (0.70) PIK3CDHPGDSASH1LFTOPIK3CB
SCHEMBL10945814 0.80 PIK3CD (0.75) PIK3CDHPGDSASH1LFTOPIK3CB
SCHEMBL28931527 0.80 TSHR (0.55) MAP2K4TTRCAMKK2FOLH1
SCHEMBL27504678 0.80 PIK3CD (0.64) PIK3CDHPGDSASH1LFTOPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 PIK3CD 3805/4885HPGDS 281/4885AURKA 4022/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 PIK3CD 3584/4885HPGDS 283/4885AURKA 3867/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 PIK3CD 3805/4885HPGDS 281/4885AURKA 4022/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR PIK3CD 3373/4885HPGDS 217/4885AURKA 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.